Excedrin Migraine Has Untapped Growth Potential, Novartis Says
This article was originally published in The Tan Sheet
Executive Summary
Novartis sees further promotion of Excedrin Migraine as an "unexploited opportunity" to expand the brand's presence and grow the firm's OTC category